SLC19A3 anticorps (C-Term)

N° du produit ABIN5516361

Cet anticorps Lapin Polyclonal détecte spécifiquement SLC19A3 dans WB. Il présente une réactivité avec des échantillons de Humain.

Aperçu rapide pour SLC19A3 anticorps (C-Term) (ABIN5516361)

Antigène: SLC19A3 (Slc19a3) (Solute Carrier Family 19, Member 3 (Slc19a3))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp SLC19A3 est non-conjugé

Application: Western Blotting (WB)

Détail du produit anti-SLC19A3 anticorps

Épitope: C-Term

Fonction: SLC19A3 Antibody - C-terminal region

Séquence: VYGSYFAVIA GIFLMRSMYI TYSTKSQKDV QSPAPSENPD VSHPEEESNI

Purification: Affinity purified

Immunogène: The immunogen is a synthetic peptide directed towards the C terminal region of human SLC19A3

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Commentaires:

We also sell a specific blocking peptide that can be used in combination with this antibody. You can find the blocking peptide under AAP74823-100UG

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.5 mg/mL

Buffer: Purified antibody supplied in 1x PBS buffer with 0.09 % (w/v) sodium azide and 2 % sucrose.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: prevent freeze-thaw cycles

Stock: 4 °C,-20 °C

Stockage commentaire: For short term use, store at 2-8C up to 1 week. For long term storage, store at -20 °C in small aliquots to prevent freeze-thaw cycles.

Détails sur SLC19A3

Antigène: SLC19A3 (Slc19a3) (Solute Carrier Family 19, Member 3 (Slc19a3))

Autre désignation: SLC19A3

Sujet:

Background Information: This gene encodes a ubiquitously expressed transmembrane thiamine transporter that lacks folate transport activity. Mutations in this gene cause biotin-responsive basal ganglia disease (BBGD); a recessive disorder manifested in childhood that progresses to chronic encephalopathy, dystonia, quadriparesis, and death if untreated. Patients with BBGD have bilateral necrosis in the head of the caudate nucleus and in the putamen. Administration of high doses of biotin in the early progression of the disorder eliminates pathological symptoms while delayed treatment results in residual paraparesis, mild mental retardation, or dystonia. Administration of thiamine is ineffective in the treatment of this disorder. Experiments have failed to show that this protein can transport biotin. Mutations in this gene also cause a Wernicke's-like encephalopathy.

Gene Name: solute carrier family 19 member 3

Alternative Symbols: BBGD, THMD2, THTR2, thTr-2

Protein Name: thiamine transporter 2

Poids moléculaire: 55 kDa

ID gène: 80704

NCBI Accession: NP_079519

UniProt: Q9BZV2

Pathways: Dicarboxylic Acid Transport